**Traders see little chance of a new COVID variant of concern (VOC) designated by WHO before 2027, with "No" at 91%.** Current circulation centers on JN.1-descendant lineages tracked as variants under monitoring, including XFG (dominant in parts of the U.S. and globally), NB.1.8.1, PQ.16.1.1, and BA.3.2. These show immune evasion and transmissibility advantages typical of Omicron sublineages but lack evidence of substantially higher severity, disease burden, or other traits that would trigger VOC status. Recent data through mid-to-late 2026 confirm stable or declining proportions for most monitored strains, with no surge in hospitalizations or ICU admissions tied to novel mutations. WHO risk assessments rate the global public health threat as moderate, and authorities have focused on routine vaccine updates—such as the FDA advisory panel's recommendation for an XFG-targeted formulation for the 2026–2027 season—rather than emergency measures. Summer case increases tracked via wastewater and sequencing reflect expected seasonal patterns within existing lineages, not the emergence of a high-impact new variant. With only a few months remaining until 2027 and ongoing genomic surveillance showing predictable evolution without alarming signals, the market reflects consensus that a sudden VOC designation is improbable absent unexpected compensatory mutations or rapid fitness gains. Resolution hinges on official WHO action based on established criteria for transmissibility, severity, or immune impact.